Roy Beveridge, MD

home / authors / roy-beveridge-md

Articles

A panel of 4 experts on CLL

August 19th 2024

Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Ryan Haumschild, PharmD, MS, MBA, CPEL Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts discuss future directions of BTK inhibitors.

A panel of 4 experts on CLL

August 19th 2024

Patient Access Advocacy for BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA, CPEL Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of specialists discuss patient access advocacy for BTK inhibitors.

A panel of 4 experts on CLL

August 12th 2024

The Inflation Reduction Act: Implications for Patient Access in CL

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A group of experts discuss implications for patient access in CLL.

A panel of 4 experts on CLL

August 12th 2024

Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of experts discuss navigating access challenges in CLL treatment.

A panel of 4 experts on CLL

August 5th 2024

Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts discuss financial challenges of BTK inhibitor therapy.

A panel of 4 experts on CLL

August 5th 2024

Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of experts discuss combination regimens with BTK inhibitors.

A panel of 4 experts on CLL

July 29th 2024

Decision-Making in CLL: The Role of Real-World Evidence

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A discussion on therapeutic decision-making in CLL and the role of real-world evidence.

A panel of 4 experts on CLL

July 29th 2024

Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

A panel of 4 experts on CLL

July 23rd 2024

Optimizing Therapy Sequencing in CLL

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of experts discuss optimizing therapy sequencing in CLL.

A panel of 4 experts on CLL

July 23rd 2024

Empowering Patients: Key Considerations for BTK Inhibitor Adherence

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A conversation on how to empower patients and the considerations for BTK inhibitor adherence.

A panel of 4 experts on CLL

July 12th 2024

Factors Influencing Choice of Second-Generation BTKi Monotherapy

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Specialists discuss factors influencing the choices of second-generation BTK monotherapy.

A panel of 4 experts on CLL

July 12th 2024

Evaluating Value of BTK Inhibitors in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts evaluate the value of BTK inhibitors in CLL treatment.

A panel of 4 experts on CLL

June 28th 2024

CLL Treatment Landscape: Overview of BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.

A panel of 4 experts on CLL

June 28th 2024

Recent Trends and Innovations in the Management of CLL

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD

Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.

March 31st 2015

Cost Differential by Site of Service for Cancer Patients Receiving Chemotherapy

Jad Hayes, MS, ASA, MAAA J. Russell Hoverman, MD, PhD Matthew E. Brow, BA Dana C. Dilbeck, BA Diana K. Verrilli, MS Jody Garey, PharmD Janet L. Espirito, PharmD Jorge Cardona, BS Roy Beveridge, MD

The cost of care for patients receiving chemotherapy in community oncology clinics is lower than for comparable patients receiving chemotherapy in the hospital outpatient setting.

Latest Updated Articles

Transgender | Image credit: Olga Tsikarishvili - stock.adobe.com

Published: August 18th 2025 | Updated: August 25th 2025

Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults

Semaglutide | Image credit: Peter Hansen - stock.adobe.com

Published: August 19th 2025 | Updated: August 22nd 2025

Semaglutide Not Associated With Increased Risk of Eye Disorders

On-body delivery system | Image credit: Enable Injections

Published: June 6th 2025 | Updated: August 18th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

drug shortages in the US | Image credit: OntheRun Photo - stock.adobe.com

Published: June 27th 2025 | Updated: July 1st 2025

Report Reveals Mounting Burdens of Drug Shortages on US Health System

AJMC

Published: February 20th 2025 | Updated: February 21st 2025

Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP

Hands holding pack of cigarettes | Image credit: Nopphon – stock.adobe.com

Published: January 16th 2025 | Updated: January 29th 2025

FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions